Advertisement

Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia

  • Pratima Chowdary
Progress in Hematology Current progress and future direction in the treatment for hemophilia
  • 91 Downloads

Abstract

Novel approaches to the treatment of haemophilia are needed due to the limitations of the current standard of care, factor replacement therapy. Aspirations include lessening the treatment burden and effectively preventing joint damage. Treating haemophilia by restoring thrombin generation may be an effective approach. A promising target for restoring thrombin generation is tissue factor pathway inhibitor (TFPI), a multivalent Kunitz-type serine protease inhibitor that regulates tissue factor-induced coagulation via factor Xa-dependent feedback inhibition of the tissue factor–factor VIIa complex. Inhibition of TFPI reverts the coagulation process to a more primitive state evolutionarily, whilst regulation by other natural inhibitors is preserved. An aptamer and three monoclonal antibodies directed against TFPI have been investigated in clinical trials. As well as improving thrombin generation in the range associated with mild haemophilia, anti-TFPI therapies have the advantage of subcutaneous administration. However, the therapeutic window needs to be defined along with the potential for complications due to the novel mechanism of action. This review provides an overview of TFPI, its role in normal coagulation, the rationale for TFPI inhibition, and a summary of anti-TFPI therapies, previously or currently in development.

Keywords

Tissue factor pathway inhibitor Haemophilia Monoclonal antibodies Coagulation 

Notes

Compliance with ethical standards

Conflict of interest

PC has worked as an investigator on the anti-TFPI mAb for Novo Nordisk and Bayer; has received honoraria from Baxalta/Shire, Biogen Idec, CSL Behring, Novo Nordisk, Pfizer, Roche, and Sobi; has served on advisory boards for Bayer, Baxalta/Shire, Biogen Idec, CSL Behring, Chugai, Freeline, Novo Nordisk, Pfizer, Roche, and Sobi; and has received research funding from Bayer, CSL Behring, Novo Nordisk, Pfizer, and SOBI.

References

  1. 1.
    Mannucci PM, Tuddenham EG. The hemophilias—from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773–9.CrossRefGoogle Scholar
  2. 2.
    White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560.CrossRefGoogle Scholar
  3. 3.
    Valentino LA. Secondary prophylaxis therapy: what are the benefits, limitations and unknowns? Haemophilia. 2004;10(2):147–57.CrossRefGoogle Scholar
  4. 4.
    Larsson SA. Life expectancy of Swedish haemophiliacs, 1831–1980. Br J Haematol. 1985;59(4):593–602.CrossRefGoogle Scholar
  5. 5.
    Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47.CrossRefGoogle Scholar
  6. 6.
    Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388(10040):187–97.CrossRefGoogle Scholar
  7. 7.
    Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992;232(1):25–32.CrossRefGoogle Scholar
  8. 8.
    Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535–44.CrossRefGoogle Scholar
  9. 9.
    Skinner MW. WFH: closing the global gap–achieving optimal care. Haemophilia. 2012;18(Suppl 4):1–12.CrossRefGoogle Scholar
  10. 10.
    Collins PW, Blanchette VS, Fischer K, Bjorkman S, Oh M, Fritsch S, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009;7(3):413–20.CrossRefGoogle Scholar
  11. 11.
    Collins PW, Bjorkman S, Fischer K, Blanchette V, Oh M, Schroth P, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. 2010;8(2):269–75.CrossRefGoogle Scholar
  12. 12.
    Collins PW. Personalized prophylaxis. Haemophilia. 2012;18(Suppl 4):131–5.CrossRefGoogle Scholar
  13. 13.
    Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia. 2014;20(5):607–15.CrossRefGoogle Scholar
  14. 14.
    Broderick CR, Herbert RD, Latimer J, Barnes C, Curtin JA, Mathieu E, et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA. 2012;308(14):1452–9.CrossRefGoogle Scholar
  15. 15.
    Richards M, Williams M, Chalmers E, Liesner R, Collins P, Vidler V, et al. A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol. 2010;149(4):498–507.CrossRefGoogle Scholar
  16. 16.
    Fischer K, Collins PW, Ozelo MC, Srivastava A, Young G, Blanchette VS. When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. J Thromb Haemost. 2016;14(5):1105–9.CrossRefGoogle Scholar
  17. 17.
    Thornburg CD, Carpenter S, Zappa S, Munn J, Leissinger C. Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States. Haemophilia. 2012;18(4):568–74.CrossRefGoogle Scholar
  18. 18.
    Collins P, Chalmers E, Chowdary P, Keeling D, Mathias M, O’Donnell J, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia. 2016;22(4):487–98.CrossRefGoogle Scholar
  19. 19.
    Young G, Mahlangu JN. Extended half-life clotting factor concentrates: results from published clinical trials. Haemophilia. 2016;22(Suppl 5):25–30.CrossRefGoogle Scholar
  20. 20.
    Mei B, Pan C, Jiang H, Tjandra H, Strauss J, Chen Y, et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood. 2010;116(2):270–9.CrossRefGoogle Scholar
  21. 21.
    Collins PW, Chalmers E, Hart DP, Liesner R, Rangarajan S, Talks K, et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol. 2013;160(2):153–70.CrossRefGoogle Scholar
  22. 22.
    Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809–18.CrossRefGoogle Scholar
  23. 23.
    Hedner U, Lee CA. First 20 years with recombinant FVIIa (NovoSeven). Haemophilia. 2011;17(1):e172-82.CrossRefGoogle Scholar
  24. 24.
    Giansily-Blaizot M, Schved JF. Recombinant human factor VIIa (rFVIIa) in hemophilia: mode of action and evidence to date. Ther Adv Hematol. 2017;8(12):345–52.CrossRefGoogle Scholar
  25. 25.
    Hoffman M, Monroe DM 3rd. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Dis Mon. 2003;49(1):14–21.PubMedGoogle Scholar
  26. 26.
    Varadi K, Tangada S, Loeschberger M, Montsch P, Schrenk G, Ewenstein B, et al. Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA® in prophylactic therapy. Haemophilia. 2016;22(4):615–24.CrossRefGoogle Scholar
  27. 27.
    Leissinger C, Gringeri A, Antmen B, Berntorp E, Biasoli C, Carpenter S, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011;365(18):1684–92.CrossRefGoogle Scholar
  28. 28.
    Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia. 2007;13(3):249–55.CrossRefGoogle Scholar
  29. 29.
    Franchini M, Coppola A, Tagliaferri A, Lippi G. FEIBA versus NovoSeven in hemophilia patients with inhibitors. Semin Thromb Hemost. 2013;39(7):772–8.CrossRefGoogle Scholar
  30. 30.
    Chai-Adisaksopha C, Nevitt SJ, Simpson ML, Janbain M, Konkle BA. Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors. Cochrane Database Syst Rev. 2017;9:Cd011441.PubMedGoogle Scholar
  31. 31.
    Scott LJ, Kim ES. Emicizumab-kxwh: First global approval. Drugs. 2018;78(2):269–74.CrossRefGoogle Scholar
  32. 32.
    Pasi KJ, Rangarajan S, Georgiev P, Mant T, Creagh MD, Lissitchkov T, et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med. 2017;377(9):819–28.CrossRefGoogle Scholar
  33. 33.
    Chowdary P, Lethagen S, Friedrich U, Brand B, Hay C, Abdul Karim F, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015;13(5):743–54.CrossRefGoogle Scholar
  34. 34.
    Hilden I, Lauritzen B, Sorensen BB, Clausen JT, Jespersgaard C, Krogh BO, et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood. 2012;119(24):5871–8.CrossRefGoogle Scholar
  35. 35.
    Cardinal M, Kantaridis C, Zhu T, Sun P, Pittman DD, Murphy JE, et al. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers. J Thromb Haemost. 2018;16(9):1722–31.CrossRefGoogle Scholar
  36. 36.
    Paz P, Xie J, Aswad F. Antibody engineering of anti-TFPI bypass therapeutic BAY 1093884: Isotype selection and sequence optimization. Blood. 2015;126(23):3496.Google Scholar
  37. 37.
    Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood. 1988;71(2):335–43.PubMedGoogle Scholar
  38. 38.
    Baugh RJ, Broze GJ Jr, Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem. 1998;273(8):4378–86.CrossRefGoogle Scholar
  39. 39.
    Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature. 1989;338(6215):518–20.CrossRefGoogle Scholar
  40. 40.
    Wood JP, Bunce MW, Maroney SA, Tracy PB, Camire RM, Mast AE. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci USA. 2013;110(44):17838–43.CrossRefGoogle Scholar
  41. 41.
    Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ Jr. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem. 1988;263(13):6001–4.PubMedGoogle Scholar
  42. 42.
    Broze GJ Jr, Girard TJ. Tissue factor pathway inhibitor: structure-function. Front Biosci (Landmark Ed). 2012;17:262–80.CrossRefGoogle Scholar
  43. 43.
    Mast AE. Tissue factor pathway inhibitor: Multiple anticoagulant activities for a single protein. Arterioscler Thromb Vasc Biol. 2016;36(1):9–14.CrossRefGoogle Scholar
  44. 44.
    Petersen LC, Bjorn SE, Olsen OH, Nordfang O, Norris F, Norris K. Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor. Eur J Biochem. 1996;235(1–2):310–6.CrossRefGoogle Scholar
  45. 45.
    Hamuro T, Kido H, Asada Y, Hatakeyama K, Okumura Y, Kunori Y, et al. Tissue factor pathway inhibitor is highly susceptible to chymase-mediated proteolysis. FEBS J. 2007;274(12):3065–77.CrossRefGoogle Scholar
  46. 46.
    Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA. 1990;87(22):8869–73.CrossRefGoogle Scholar
  47. 47.
    Wood JP, Ellery PE, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood. 2014;123(19):2934–43.CrossRefGoogle Scholar
  48. 48.
    Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem. 1989;264(31):18832–7.PubMedGoogle Scholar
  49. 49.
    Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood. 1988;72(6):2020–5.PubMedGoogle Scholar
  50. 50.
    Maroney SA, Ferrel JP, Pan S, White TA, Simari RD, McVey JH, et al. Temporal expression of alternatively spliced forms of tissue factor pathway inhibitor in mice. J Thromb Haemost. 2009;7(7):1106–13.CrossRefGoogle Scholar
  51. 51.
    Maroney SA, Mast AE. Expression of tissue factor pathway inhibitor by endothelial cells and platelets. Transfus Apher Sci. 2008;38(1):9–14.CrossRefGoogle Scholar
  52. 52.
    Maroney SA, Haberichter SL, Friese P, Collins ML, Ferrel JP, Dale GL, et al. Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. Blood. 2007;109(5):1931–7.CrossRefGoogle Scholar
  53. 53.
    Girard TJ, Tuley E, Broze GJ Jr. TFPIbeta is the GPI-anchored TFPI isoform on human endothelial cells and placental microsomes. Blood. 2012;119(5):1256–62.CrossRefGoogle Scholar
  54. 54.
    Bajaj MS, Kuppuswamy MN, Manepalli AN, Bajaj SP. Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues. Thromb Haemost. 1999;82(3):1047–52.PubMedGoogle Scholar
  55. 55.
    Ellery PER, Hilden I, Sejling K, Loftager M, Martinez ND, Maroney SA, et al. Correlates of plasma and platelet tissue factor pathway inhibitor, factor V, and Protein S. Res Pract Thromb Haemost. 2018;2(1):93–104.CrossRefGoogle Scholar
  56. 56.
    Aird WC. Spatial and temporal dynamics of the endothelium. J Thromb Haemost. 2005;3(7):1392–406.CrossRefGoogle Scholar
  57. 57.
    Rosenberg RD, Aird WC. Vascular-bed–specific hemostasis and hypercoagulable states. N Engl J Med. 1999;340(20):1555–64.CrossRefGoogle Scholar
  58. 58.
    Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359(9):938–49.CrossRefGoogle Scholar
  59. 59.
    Kim K, Hahm E, Li J, Holbrook LM, Sasikumar P, Stanley RG, et al. Platelet protein disulfide isomerase is required for thrombus formation but not for hemostasis in mice. Blood. 2013;122(6):1052–61.CrossRefGoogle Scholar
  60. 60.
    Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res. 2007;100(2):158–73.CrossRefGoogle Scholar
  61. 61.
    Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol. 2006;26(1):41–8.CrossRefGoogle Scholar
  62. 62.
    Butenas S, van’t Veer C, Mann KG. “Normal” thrombin generation. Blood. 1999;94(7):2169–78.PubMedGoogle Scholar
  63. 63.
    Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33(1):4–15.CrossRefGoogle Scholar
  64. 64.
    Davidson CJ, Tuddenham EG, McVey JH. 450 million years of hemostasis. J Thromb Haemost. 2003;1(7):1487–94.CrossRefGoogle Scholar
  65. 65.
    Doolittle RF. Bioinformatic characterization of genes and proteins involved in blood clotting in lampreys. J Mol Evol. 2015;81(3–4):121–30.CrossRefGoogle Scholar
  66. 66.
    Krishnaswamy S. The transition of prothrombin to thrombin. J Thromb Haemost. 2013;11(Suppl 1):265–76.CrossRefGoogle Scholar
  67. 67.
    Hackeng TM, Sere KM, Tans G, Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA. 2006;103(9):3106–11.CrossRefGoogle Scholar
  68. 68.
    Ndonwi M, Tuley EA, Broze GJ Jr. The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition. Blood. 2010;116(8):1344–51.CrossRefGoogle Scholar
  69. 69.
    Wood JP, Ellery PE, Maroney SA, Mast AE. Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-alpha but not for cell surface-associated tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol. 2014;34(1):169–76.CrossRefGoogle Scholar
  70. 70.
    Song K-M, Lee S, Ban C. Aptamers and their biological applications. Sensors (Basel Switzerland). 2012;12(1):612–31.CrossRefGoogle Scholar
  71. 71.
    Waters EK, Genga RM, Schwartz MC, Nelson JA, Schaub RG, Olson KA, et al. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Blood. 2011;117(20):5514–22.CrossRefGoogle Scholar
  72. 72.
    Dockal M, Pachlinger R, Hartmann R, Knappe S, Sorensen B, Wong WY, et al. Biological explanation of clinically observed elevation of TFPI plasma levels after treatment with TFPI-antagonistic aptamer BAX 499. Blood. 2012;120(21):1104.Google Scholar
  73. 73.
    Llorente-Cortés V, Badimon L. LDL receptor-related protein and the vascular wall. Implic Atherothromb. 2005;25(3):497–504.Google Scholar
  74. 74.
    Waters EK, Genga RM, Thomson HA, Kurz JC, Schaub RG, Scheiflinger F, et al. Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein. J Thromb Haemost. 2013;11(6):1137–45.CrossRefGoogle Scholar
  75. 75.
    Gissel M, Orfeo T, Foley JH, Butenas S. Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia. Thromb Res. 2012;130(6):948–55.CrossRefGoogle Scholar
  76. 76.
    Dockal M, Hartmann R, Knappe S, Palige M, Kammlander W, Kunckova K, et al. Effect of increased tissue factor pathway inhibitor (TFPI) levels on factor Xa inhibition and global hemostasis in the presence of TFPI-antagonistic aptamer BAX 499. Blood. 2012;120(21):2207.Google Scholar
  77. 77.
    Nordfang O, Valentin S, Beck TC, Hedner U. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma. Thromb Haemost. 1991;66(4):464–7.CrossRefGoogle Scholar
  78. 78.
    Erhardtsen E, Ezban M, Madsen MT, Diness V, Glazer S, Hedner U, et al. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul Fibrinolysis. 1995;6(5):388–94.CrossRefGoogle Scholar
  79. 79.
    Maroney SA, Cooley BC, Ferrel JP, Bonesho CE, Nielsen LV, Johansen PB, et al. Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia. Proc Natl Acad Sci USA. 2012;109(10):3927–31.CrossRefGoogle Scholar
  80. 80.
    Waters EK, Sigh J, Friedrich U, Hilden I, Sorensen BB. Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay. Haemophilia. 2017;23(5):769–76.CrossRefGoogle Scholar
  81. 81.
    Eichler H, Angchaisuksiri P, Kavakli K, Knoebl P, Windyga J, Jimenez-Yuste V, et al. Safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A: a phase 1b, randomized trial. J Thromb Haemost. 2018.  https://doi.org/10.1111/jth.14272. (epub ahead of print Aug 23).CrossRefPubMedGoogle Scholar
  82. 82.
    Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol. 2006;72(1):1–10.CrossRefGoogle Scholar
  83. 83.
    Parng C, Singh P, Pittman DD, Wright K, Leary B, Patel-Hett S, et al. Translational pharmacokinetic/pharmacodynamic characterization and target-mediated drug disposition modeling of an anti-tissue factor pathway inhibitor antibody, PF-06741086. J Pharm Sci. 2018;107(7):1995–2004.CrossRefGoogle Scholar
  84. 84.
    Jasuja R, Barakat A, Murphy JE, Pittman DD. An antibody to tissue factor pathway inhibitor (TFPI) restores hemostasis after the onset of bleeding in hemophilic A mouse injury models. Blood. 2016;128:3761.Google Scholar
  85. 85.
    Gu JM, Zhao XY, Schwarz T, Schuhmacher J, Baumann A, Ho E, et al. Mechanistic modeling of the pharmacodynamic and pharmacokinetic relationship of tissue factor pathway inhibitor-neutralizing antibody (BAY 1093884) in cynomolgus monkeys. AAPS J. 2017;19(4):1186–95.CrossRefGoogle Scholar
  86. 86.
    McVey JH. The role of the tissue factor pathway in haemostasis and beyond. Curr Opin Hematol. 2016;23(5):453–61.CrossRefGoogle Scholar
  87. 87.
    Dargaud Y, Simpson H, Chevalier Y, Scoazec JY, Hot A, Guyen O, et al. The potential role of synovial thrombomodulin in the pathophysiology of joint bleeds in haemophilia. Haemophilia. 2012;18(5):818–23.CrossRefGoogle Scholar
  88. 88.
    Lee BB, Baumgartner I, Berlien P, Bianchini G, Burrows P, Gloviczki P, et al. Diagnosis and treatment of venous malformations. Consensus document of the International Union of Phlebology (IUP): updated 2013. Int Angiol. 2015;34(2):97–149.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  1. 1.KD Haemophilia and Thrombosis CentreRoyal Free London NHS Foundation TrustLondonUK

Personalised recommendations